Tazarotene Revisited: Safety and Efficacy in Plaque Psoriasis and its Emerging Role in Treatment Strategy
Tanghetti, E.; Lebwohl, M.; Stein Gold, L.
Journal of Drugs in Dermatology Jdd 17(12): 1280-1287
2018
ISSN/ISBN: 1545-9616 PMID: 30586259 Document Number: 17667
Background: Psoriasis is a chronic, immune-mediated disease that varies widely in its clinical expression. Treatment options focus on relieving symptoms, reducing inflammation, induration, and scaling, and controlling the extent of the disease. While significant data on tazarotene in psoriasis has been available for over 20 years, its main utility is in acne.
Document emailed within 1 workday
Related Documents
Lebwohl, M.G..; Sugarman, J.L..; Stein Gold, L.; Lin, T.; Israel, R. 2019: Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of two Phase IIi Randomized Controlled Trials Journal of Drugs in Dermatology: Jdd 18(10): 1012-1018Jarratt, M.T.; Clark, S.D.; Savin, R.C.; Swinyer, L.J.; Safley, C.F.; Brodell, R.T.; Yu, K. 2006: Evaluation of the efficacy and safety of clobetasol propionate spray in the treatment of plaque-type psoriasis Cutis 78(5): 348-354
Beutner, K.; Chakrabarty, A.; Lemke, S.; Yu, K. 2006: An intra-individual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque psoriasis Journal of Drugs in Dermatology: Jdd 5(4): 357-360
Pariser, D.M.; Green, L.J.; Stein Gold, L.; Sugarman, J.L.; Lin, T.; Pillai, R. 2018: Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy Journal of Drugs in Dermatology: Jdd 17(7): 723-726
Hudson, C.P.; Kempers, S.; Menter, A.; Papp, K.; Smith, S.; Sofen, H.; Colón, L.E.; Johnson, L.A.; Gottschalk, R. 2011: An open-label, multicenter study of the efficacy and safety of a weekday/weekend treatment regimen with calcitriol ointment 3 microg/g and clobetasol propionate spray 0.05% in the management of plaque psoriasis Cutis 88(4): 201-207
Vender, R. 2011: An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab Journal of Drugs in Dermatology: Jdd 10(4): 396-402
Feldman, S.R.; Mills, M.; Brundage, T.; Eastman, W.J. 2013: A multicenter, randomized, double-blind study of the efficacy and safety of calcipotriene foam, 0.005%, vs vehicle foam in the treatment of plaque-type psoriasis of the scalp Journal of Drugs in Dermatology: Jdd 12(3): 300-306
Strober, B.; Bagel, J.; Lebwohl, M.; Stein Gold, L.; Jackson, J.M.; Chen, R.; Goncalves, J.; Levi, E.; Callis Duffin, K. 2017: Efficacy and Safety of Apremilast in Patients with Moderate Plaque Psoriasis with Lower BSA: Week 16 Results from the UNVEIL Study Journal of Drugs in Dermatology: Jdd 16(8): 801-808
Stein Gold, L.; Kircik, L.H.; Pariser, D.; Sugarman, J.L.; Lin, T.; Kang, R.; Pillai, R. 2018: Rapid Onset of Action in Patients with Moderate-to-Severe Plaque Psoriasis with Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination Journal of Drugs in Dermatology: Jdd 17(8): 863-868
Zhu, X.; Zheng, M.; Song, M.; Shen, Y.-K.; Chan, D.; Szapary, P.O.; Wang, B.; Wang, B.; Tu, C.; Hao, F.; Jin, H.; Xu, J.; Gu, J.; Zheng, M.; Gao, T.; Lai, W.; Liu, X.; Gao, X.; Zhu, X.; Zhang, J.; Zheng, J. 2013: Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS) Journal of Drugs in Dermatology: Jdd 12(2): 166-174
Tanghetti, E.; Dhawan, S.; Green, L.; Del Rosso, J.; Draelos, Z.; Leyden, J.; Shalita, A.; Glaser, D.A.; Grimes, P.; Webster, G.; Barnett, P.; Le Gall, N. 2010: Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgaris Journal of Drugs in Dermatology: Jdd 9(5): 549-558
Kampitak, T.; Asawanonda, P. 2006: The efficacy of combination treatment with narrowband UVB (TL-01) and acitretin vs narrowband UVB alone in plaque-type psoriasis: a retrospective study Journal of the Medical Association of Thailand 89(Suppl 3): S20-S24
Ardigò, M.; Giuliani, A.; de Felice, C.; Mastroianni, A.; Berardesca, E. 2008: Efficacy of adalimumab in plaque psoriasis: experience on 28 patients Journal of Drugs in Dermatology: Jdd 7(10): 935-939
Scher, R.K.; Stiller, M.; Zhu, Y.I. 2001: Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study Cutis 68(5): 355-358
Lebwohl, M. 1998: Clinical efficacy and safety of tazarotene: optimizing clinical results Cutis 61(2 Suppl): 27-29
Gottlieb, A.B.; Matheson, R.T.; Menter, A.; Leonardi, C.L.; Day, R.M.; Hu, C.; Schafer, P.H.; Krueger, J.G. 2013: Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase Ii open-label study Journal of Drugs in Dermatology: Jdd 12(8): 888-897
Gottlieb, A.B.; Gordon, K.B.; Lebwohl, M.G.; Caro, I.; Walicke, P.A.; Li, N.; Leonardi, C.L. 2004: Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis Journal of Drugs in Dermatology: Jdd 3(6): 614-624
Tanghetti, E.; Abramovits, W.; Solomon, B.; Loven, K.; Shalita, A. 2006: Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double-blind, randomized parallel-group trial Journal of Drugs in Dermatology: Jdd 5(3): 256-261
Platt, K.; Moritis, K.; Johnson, M.R.; Berg, J.; Dunn, J.R. 2002: Clinical evaluation of the plaque removal efficacy and safety of the Sonicare Elite toothbrush American Journal of Dentistry 15(Special Issue): 18b-22b
Au, S-Chung.; Madani, A.; Alhaddad, M.; Alkofide, M.; Gottlieb, A.B. 2013: Comparison of the efficacy of biologics versus conventional systemic therapies in the treatment of psoriasis at a comprehensive psoriasis care center Journal of drugs in dermatology: JDD 12(8): 861-866